Compositions and methods for minimizing adverse drug...

Details Compositions and methods for minimizing adverse drug... Compositions and methods for minimizing adverse drug...

2006-07-25

2006-07-25

Venkat, Jyothsna (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Web, sheet or filament bases; compositions of bandages; or...

C424S448000

Reexamination Certificate

active

07081252

ABSTRACT:
The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.

REFERENCES:
patent: 4652441 (1987-03-01), Okada et al.
patent: 4959217 (1990-09-01), Sanders et al.
patent: 5028430 (1991-07-01), Sanders et al.
patent: 5152997 (1992-10-01), Ebert et al.
patent: 5164190 (1992-11-01), Patel et al.
patent: 5212199 (1993-05-01), Heiber et al.
patent: 5227169 (1993-07-01), Heiber et al.
patent: 5411740 (1995-05-01), Lee et al.
patent: 5500222 (1996-03-01), Lee et al.
patent: 5516808 (1996-05-01), Sawaya
patent: 5532278 (1996-07-01), Aberg et al.
patent: 5575987 (1996-11-01), Kamei et al.
patent: 5582838 (1996-12-01), Rork et al.
patent: 5601839 (1997-02-01), Quan et al.
patent: 5614211 (1997-03-01), Gale et al.
patent: 5626866 (1997-05-01), Ebert et al.
patent: 5641504 (1997-06-01), Lee et al.
patent: 5643584 (1997-07-01), Farng et al.
patent: 5674895 (1997-10-01), Guittard et al.
patent: 5677346 (1997-10-01), Aberg et al.
patent: 5721275 (1998-02-01), Bazzano
patent: 5736577 (1998-04-01), Aberg et al.
patent: 5747065 (1998-05-01), Lee et al.
patent: 5759583 (1998-06-01), Iwamoto et al.
patent: 5762953 (1998-06-01), Venkateshwaran
patent: 5783208 (1998-07-01), Venkateshwaran et al.
patent: 5840754 (1998-11-01), Guittard et al.
patent: 5862555 (1999-01-01), Furuhashi
patent: 5891462 (1999-04-01), Carrara
patent: 5891920 (1999-04-01), Hirano et al.
patent: 5900250 (1999-05-01), Lee et al.
patent: 5912268 (1999-06-01), Guittard et al.
patent: 5922342 (1999-07-01), Shah et al.
patent: 5939094 (1999-08-01), Durif et al.
patent: 5948433 (1999-09-01), Burton et al.
patent: 5972369 (1999-10-01), Roorda et al.
patent: 5985305 (1999-11-01), Perry et al.
patent: 5985317 (1999-11-01), Venkateshwaran et al.
patent: 6039967 (2000-03-01), Ottoboni et al.
patent: 6096339 (2000-08-01), Ayer et al.
patent: 6187323 (2001-02-01), Aiache et al.
patent: 6203817 (2001-03-01), Cormier et al.
patent: 6258830 (2001-07-01), Charu
patent: 6319913 (2001-11-01), Mak et al.
patent: 6562368 (2003-05-01), Hsu et al.
patent: 2001/0031787 (2001-10-01), Hsu et al.
patent: 2002/0147236 (2002-10-01), Sanders et al.
patent: 2002/0161044 (2002-10-01), Sherratt et al.
patent: WO 92/10231 (1992-06-01), None
patent: WO 92/20377 (1992-11-01), None
patent: WO 93/23025 (1993-11-01), None
patent: WO 95/09007 (1995-04-01), None
patent: WO 99/48493 (1999-09-01), None
patent: WO 99/48494 (1999-09-01), None
patent: WO 99/48493 (1999-09-01), None
L. Noronha-Blob and J. F. Kachur,Enantiomers of Oxybutynin: In Vitro Pharmacological Characterization at M1, M2and M3Muscarinic Receptors and in Vivo Effects on Urinary Bladder Contraction, Mydriasis and alivary Secretion in Guinea Pigs, Journal of Pharmacology and Experimental Therapeutics, 256: 562-567, (1990).
Ernest W. Merritt and Eugene R. Cooper,Diffusion Apparatus for Skin Penetration, Journal of Controlled Release, 1: 161-162, (1984).
James F. Kachur, Jan S. Peterson, J. Paul Carter, W. Janusz Rzeszotarski, Robert C. Hanson and Lalita Noronha-Blob,R and S Enantiomers of Oxybutynin: Pharmacological Effects in Guinea Pig Bladder and Intestine, The Journal of Pharmacology and Experimental Therapeutics, 247: 3, 867-872, (1988).
Buyse, Gunnar et al., “Intravesical Oxybutynin for Neurogenic Bladder Dysfunction: Less Systemic Side Effects Due to Reduced first Pass Metabolism,” The Journal of Urology, Sep. 1998, pp. 892-896, vol. 160.
Gupta, Suneel K. (Ph.D) et al., “Pharmacokinetics of an Oral Once-a-Day Controlled-Release Oxybutynin Formulation Compared with Immediate-Release Oxybutynin,” J. Clin. Pharmacol, 1999, pp. 289-296, vol. 39.

Affiliated with

Also associated with

Rating

Compositions and methods for minimizing adverse drug... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods for minimizing adverse drug..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for minimizing adverse drug... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3551379